Directions in Development
Human Development
ПРактИЧеское РукоВодстВо для соВместных меРоПРИятИй.
Eurosurveillance
Impact Factor 5.7
June 2015
www.eurosurveillance.org
Featuring a series of articles on HIV and STI epidemiology, prevention and control among MSM in Europe
UNAIDS/10.03E / JC1767E (English original, March 2010) ISBN 978 92 9 173849 6
Strengthening Community responses to HIv Treatment and Prevention
Le Ministère de la Santé (MS), dans le cadre de la démarche qualité au niveau du secteur, s’est engagé depuis quelques années dans la normalisation des activités par l’élaboration et la mise en place de documents normatifs. C’est le cas du présent document de politique, normes et proc...édures en matière de prise en charge des Personnes Vivant avec le VIH (PVVIH).
L’impact socio-économique et sanitaire du VIH/Sida fait désormais de cette affection, tant un problème de santé publique qu’un problème de développement. C’est donc pour ne pas laisser les personnes infectées en marge du développement de notre pays, que leur prise en charge a été identifiée comme domaine de prestation de service avec des directives nationales de prise en charge des PVVIH diffusées.
more
UNAIDS 2016 / Meeting Report
A resource for improving menstraul hygiene around the world.
Comprehensive guidance with examples of good practice, information for colleagues and pupils in class and tips on how to break the taboo
Topics in Antiviral Medicine Volume 25 Issue 2 May/June 2017
Accelerating HIV prevention to reduce new infections by 75%
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more
May 2018
HIV i-Base
ISSN 1475-2077 www.i-Base.info
Watch for out-of-date information
First questions
You and your doctor Resistance and adherence Treatment choices
In aquaculture, antibiotics have been used mainly for therapeutic purposes and as prophylactic agents. The contribution to antimicrobial resistance of antibiotics used in aquaculture is reviewed here, using a risk analysis framework. Some recommendations on responsible conduct in this context are pr...oposed, aimed at diminishing the threat of build up of antimicrobial resistance.
more
The extensive use of antimicrobials in human and veterinary medicine in recent years has accelerated the emergence and spread of resistant microorganisms. This situation has been worsened by the lack of investment in developing new effective antibiotics. The severity of the consequences is clear to ...see: it is estimated that each year, drug-resistant infections result in at least 25 000 patient deaths and cost the EU EUR 1,5 billion in healthcare costs and through loss of productivity
more
Une approche intégrée de la santé et des droits humains est essentielle pour veiller à la dignité et au bien-être des femmes vivant avec le VIH.
This briefing paper provides an overview of pre-exposure prophylaxis (PrEP) for people planning, commissioning or providing HIV prevention activities in the UK. It does this by reviewing thirty key questions about PrEP and how it might be implemented in the UK.
Prise en charge Intégrée des maladies de l’adolescent
et de l’adulte (PCIMAA)
Avril 2007
WHO/HTM/VIH/2007.01
WHO/HTM/TB/2007.380